US2014106379A1PendingUtilityA1

Immunological Test for Detecting Autoantibodies Against Testicular Antigens

Assignee: UNIV GIESSEN JUSTUS LIEBIGPriority: Oct 28, 2008Filed: Sep 9, 2013Published: Apr 17, 2014
Est. expiryOct 28, 2028(~2.3 yrs left)· nominal 20-yr term from priority
G01N 33/689G01N 33/543G01N 2333/79G01N 2800/367
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammation-related fertility disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is utilized to detect the presence of immunologically-caused and infection-related infertility in male mammals, particularly in humans.

Claims

exact text as granted — not AI-modified
1 . A kit for conducting an immunological test for the detection and the specific determination of autoantibodies which are associated with inflammation-related fertility disorders which are silent or symptomatically progressing inflammations of the testicules, epididymis, seminal ducts or accessory glands of male mammals characterized in that it comprises:
 specific testicular antigen which is adsorbed to a carrier   and a preparation of IgG antibodies which are species-specific for the male mammal to be investigated and can species-specifically bind to the autoantibodies against testicular antigens, and which are labeled in such a way that they are detected by a cascade of reactions of the biotin-streptavidin-peroxidase or -alkaline phosphatase type.   
     
     
         2 . The kit according to  claim 1 , characterized in that the specific testicular antigen is ER-60 and/or transferrin.

Join the waitlist — get patent alerts

Track US2014106379A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.